Sigma Labs, Inc. has obtained the complete assignment interest in its critical patent on advanced dental implant technology thereby enabling commercialization to proceed unencumbered. This supports Sigma Labs exclusive marketing agreement (EMA) with Manhattan Scientifics, Inc.

The EMA sets forth the parties intent to market Sigma Labs technology to prospective licensees and strategic partners. The Sigma Labs rapid healing implant uses former US National Laboratory technology to create a surface that can completely integrate with bone in four to six weeks, with attendent reduction of inflamation and patient discomfort.

Mark Cola, president and CEO of Sigma Labs, stated that, "In an continuing effort to monetize our full IP portfolio while maintaining focus on our efforts in PrintRite3D for metal 3D printing, we are pleased to work with Manhattan Scientifics to identify prospective licensees and strategic partners for our advanced dental implant technology. Manhattan Scientifics has a similar heritage of commercializing advanced technology from leading US national research institutions."

Manny Tsoupanarias, CEO of Manhattan Scientifics further stated that, "We are pleased to have the opportunity to market Sigma Labs dental technology. We feel this technology may be very attractive to the global dental implant market and potentially other implants as well. We plan to leverage our previous work and contacts within the industry to create new opportunities for both of our companies." Manny Tsoupanarias continued that "Sigma Labs technology is entirely in line with our focus on nano-medicine technologies and augments our previous work in nanomaterials for dental implants."

Sigma Labs, Inc., through its wholly-owned subsidiary B6 Sigma, Inc., develops and engineers advanced non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for 3D metal printing and other advanced manufacturing technologies.